Leukemia

Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.

After treatment, this survivor was terrified of everyone and everything until her very wise doctor said, “I did not put you through all this for you to put yourself in a bubble – go live your life.” And she has… for 16 years and counting.

This essay nominating Wilafe Tolentino, B.S.N., RN, OCN for CURE®'s Extraordinary Healer® Award was written by Dr. Fred Hardwicke, M.D., of the University Medical Center Southwest Cancer Center, Lubbock, Texas.

The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.

Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.

The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.

An extraordinary group of nurses, led by nurse manager Taylor Andrews, B.S., RN, BMTCN, have made it their mission to become fairy godmothers for the patients they care for in the bone marrow transplant unit and to make their wishes come true.

When you are first told that you’re sick, very sick, it’s like a kick in the head. It leaves you stunned and not quite sure which way to turn. If you’re as lucky as I was, you have Sandy Allen-Bard, NP, to turn to.

Most people have heard the term "new normal" for individuals living, surviving and struggling with cancer. What actually does that mean?

The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.

Extraordinary Healer® Award finalist Angela Hammack, B.S.N., RN, OCN, discussed how she began running marathons to raise awareness – and $100,000 – for cancer.

In this week’s episode, we spoke with a young adult and a child life specialist who discussed the importance of focusing on the needs of AYAs with cancer.

An expert discusses new treatment options for patients diagnosed with CLL.

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

Here are the top 5 CURE stories for March 2019.

Helping others is the last phase of recovery.

Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.

Here are the top 5 CURE stories for February 2019.

Brian Boyle, who plays center for the New Jersey Devils, has announced that his blood cancer is in remission.